News >

CTC AR-V7 Validated as Predictive Marker of Resistance to AR-Directed Therapy in mCRPC

Gina Columbus @ginacolumbusonc
Published: Wednesday, Mar 13, 2019

Andrew J. Armstrong, MD

Andrew J. Armstrong, MD

Nuclear-localized androgen receptor splice variant 7 (AR-V7) protein in circulating tumor cells (CTCs) is a predictive marker of shorter progression-free and overall survival (OS) with antiandrogen therapy in patients with metastatic castration-resistant prostate cancer (mCRPC), according to results from the phase III PROPHECY trial that were published in the Journal of Clinical Oncology.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x